Holzbeierlein JM - Search Results

1

Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor.

Khandelwal A, Kent CN, Balch M, Peng S, Mishra SJ, Deng J, Day VW, Liu W, Subramanian C, Cohen M, Holzbeierlein JM, Matts R, Blagg BSJ. Khandelwal A, et al. Among authors: holzbeierlein jm. Nat Commun. 2018 Jan 30;9(1):425. doi: 10.1038/s41467-017-02013-1. Nat Commun. 2018. PMID: 29382832 Free PMC article.

2

Hsp90 inhibitors identified from a library of novobiocin analogues.

Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BS. Yu XM, et al. J Am Chem Soc. 2005 Sep 21;127(37):12778-9. doi: 10.1021/ja0535864. J Am Chem Soc. 2005. PMID: 16159253

3

Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.

Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, Blagg BS. Burlison JA, et al. J Org Chem. 2008 Mar 21;73(6):2130-7. doi: 10.1021/jo702191a. Epub 2008 Feb 23. J Org Chem. 2008. PMID: 18293999

4

The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity.

Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein J, Blagg BS. Donnelly AC, et al. J Org Chem. 2008 Nov 21;73(22):8901-20. doi: 10.1021/jo801312r. Epub 2008 Oct 22. J Org Chem. 2008. PMID: 18939877 Free PMC article.

5

Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells.

Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, Donnelly AC, Blagg BS, Holzbeierlein JM. Matthews SB, et al. Among authors: holzbeierlein jm. Prostate. 2010 Jan 1;70(1):27-36. doi: 10.1002/pros.21035. Prostate. 2010. PMID: 19739131 Free PMC article.

6

Hsp90: a drug target?

Holzbeierlein JM, Windsperger A, Vielhauer G. Holzbeierlein JM, et al. Curr Oncol Rep. 2010 Mar;12(2):95-101. doi: 10.1007/s11912-010-0086-3. Curr Oncol Rep. 2010. PMID: 20425593 Review.

7

Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents.

Zhao H, Donnelly AC, Kusuma BR, Brandt GE, Brown D, Rajewski RA, Vielhauer G, Holzbeierlein J, Cohen MS, Blagg BS. Zhao H, et al. J Med Chem. 2011 Jun 9;54(11):3839-53. doi: 10.1021/jm200148p. Epub 2011 May 9. J Med Chem. 2011. PMID: 21553822 Free PMC article.

8

Targeting the heat shock protein 90 dimer with dimeric inhibitors.

Kusuma BR, Peterson LB, Zhao H, Vielhauer G, Holzbeierlein J, Blagg BS. Kusuma BR, et al. J Med Chem. 2011 Sep 22;54(18):6234-53. doi: 10.1021/jm200553w. Epub 2011 Aug 23. J Med Chem. 2011. PMID: 21861487 Free PMC article.

9

Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.

Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM, Vielhauer GA. Eskew JD, et al. Among authors: holzbeierlein jm. BMC Cancer. 2011 Oct 31;11:468. doi: 10.1186/1471-2407-11-468. BMC Cancer. 2011. PMID: 22039910 Free PMC article.

10

Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.

Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA. Sadikot T, et al. Among authors: holzbeierlein jm. Assay Drug Dev Technol. 2013 Oct;11(8):478-88. doi: 10.1089/adt.2012.498. Epub 2013 Oct 15. Assay Drug Dev Technol. 2013. PMID: 24127661 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

142 results

Search Page